What distinguishes lead discovery from lead optimization, and what criteria are typically used to select a lead?

Prepare for the Drug Discovery and Healthcare Systems Test. Access flashcards and multiple-choice questions with hints and explanations. Ace your exam with our comprehensive resources!

Multiple Choice

What distinguishes lead discovery from lead optimization, and what criteria are typically used to select a lead?

The main idea is that drug discovery and drug optimization are two different stages in turning a hit into a workable drug. Lead discovery is about finding initial chemical matter that shows the desired activity against a target. It involves screening large libraries, spotting hits, and evaluating them to pick a few promising leads for further development. Lead optimization then takes those leads and iteratively tweaks their structures to improve properties so they can become safe, effective, and developable drug candidates. When selecting a lead, you look at a combination of factors: potency against the target, and how selectively it hits the target versus other proteins to reduce side effects. You also assess safety signals early, such as potential toxicity in vitro, and pharmacokinetic properties like absorption, distribution, metabolism, and excretion to ensure the compound behaves well in the body. Developability considerations are also key: chemical stability, solubility, synthetic tractability, and the likelihood of scalable manufacture, all of which affect how feasible it is to advance the compound into further studies and eventual production. The aim is to pick a lead that not only works well against the target but also has a realistic chance of being safe, effective, and workable as a therapeutic. That’s why the best description is the one that says lead discovery finds initial chemical matter with desired activity, and lead optimization refines potency, selectivity, safety, PK, and developability. Statements that focus only on optimization, claim regulatory approval, or conflate the two stages don’t capture the full distinction.

The main idea is that drug discovery and drug optimization are two different stages in turning a hit into a workable drug. Lead discovery is about finding initial chemical matter that shows the desired activity against a target. It involves screening large libraries, spotting hits, and evaluating them to pick a few promising leads for further development. Lead optimization then takes those leads and iteratively tweaks their structures to improve properties so they can become safe, effective, and developable drug candidates.

When selecting a lead, you look at a combination of factors: potency against the target, and how selectively it hits the target versus other proteins to reduce side effects. You also assess safety signals early, such as potential toxicity in vitro, and pharmacokinetic properties like absorption, distribution, metabolism, and excretion to ensure the compound behaves well in the body. Developability considerations are also key: chemical stability, solubility, synthetic tractability, and the likelihood of scalable manufacture, all of which affect how feasible it is to advance the compound into further studies and eventual production. The aim is to pick a lead that not only works well against the target but also has a realistic chance of being safe, effective, and workable as a therapeutic.

That’s why the best description is the one that says lead discovery finds initial chemical matter with desired activity, and lead optimization refines potency, selectivity, safety, PK, and developability. Statements that focus only on optimization, claim regulatory approval, or conflate the two stages don’t capture the full distinction.

More practice questions